Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/kGWnGzGdNkk/264899.php
Saturday, 17 August 2013
Malaria DNA vaccine demonstrates robust immune responses in animal models
Inovio Pharmaceuticals, Inc. have announced that its SynCon� DNA vaccine containing multiple malaria antigens delivered via its CELLECTRA� electroporation device demonstrated strong and durable antibody and T-cell immune responses in small animals and non-human primates. With these strong preclinical results, Inovio plans to initiate a phase I/IIa clinical trial next year...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment